Abstract
Aim and Methods: We conducted two studies in healthy male subjects to assess the effect on serum cortisol levels of the novel inhaled corticosteroid GW870086, dosed at 6 mg, 12 mg and 15 mg/day (dry powder inhaler; NCT00549497) for 3 days and 5 mg and 8.75 mg/day (nebules; NCT01160003) for 14 days.
Results: In the 3-Day Study, the greatest suppression of serum cortisol weighted mean (0-24 hour) of GW870086, compared with placebo, was observed on Day 1 (29% suppression at the 15 mg dose). In the 14-Day Study, the greatest suppression was 15% for GW870086 5 mg. None of these values was considered clinically significant. After 3 days’ dosing, GW870086 was absorbed slowly (tmax: 0.8-3.5 hours) and eliminated with a t1/2 of 22.7 hours; the highest systemic exposure (AUC) was 26.7 ng.hour/mL. After 14 days, GW870086 tmax was 0.3-0.4 hours and t1/2 25.0-29.6 hours; the highest AUC was 16.7 ng.hour/mL. No safety issues were identified in these studies.
Conclusion: At estimated therapeutic and supratherapeutic doses, which achieved high exposure (AUC) in both studies, GW870086 did not exhibit the usual level of hypothalamic-pituitary-adrenal axis suppression that would be expected with traditional inhaled corticosteroids.
Keywords: Cortisol, GW870086, pharmacokinetics, safety.
Current Drug Therapy
Title:Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GW870086: Two Randomised Studies
Volume: 8 Issue: 2
Author(s): Ann Allen, Philippe Bareille, Kelly Hardes and Jonathan Robertson
Affiliation:
Keywords: Cortisol, GW870086, pharmacokinetics, safety.
Abstract: Aim and Methods: We conducted two studies in healthy male subjects to assess the effect on serum cortisol levels of the novel inhaled corticosteroid GW870086, dosed at 6 mg, 12 mg and 15 mg/day (dry powder inhaler; NCT00549497) for 3 days and 5 mg and 8.75 mg/day (nebules; NCT01160003) for 14 days.
Results: In the 3-Day Study, the greatest suppression of serum cortisol weighted mean (0-24 hour) of GW870086, compared with placebo, was observed on Day 1 (29% suppression at the 15 mg dose). In the 14-Day Study, the greatest suppression was 15% for GW870086 5 mg. None of these values was considered clinically significant. After 3 days’ dosing, GW870086 was absorbed slowly (tmax: 0.8-3.5 hours) and eliminated with a t1/2 of 22.7 hours; the highest systemic exposure (AUC) was 26.7 ng.hour/mL. After 14 days, GW870086 tmax was 0.3-0.4 hours and t1/2 25.0-29.6 hours; the highest AUC was 16.7 ng.hour/mL. No safety issues were identified in these studies.
Conclusion: At estimated therapeutic and supratherapeutic doses, which achieved high exposure (AUC) in both studies, GW870086 did not exhibit the usual level of hypothalamic-pituitary-adrenal axis suppression that would be expected with traditional inhaled corticosteroids.
Export Options
About this article
Cite this article as:
Allen Ann, Bareille Philippe, Hardes Kelly and Robertson Jonathan, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GW870086: Two Randomised Studies, Current Drug Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15748855113089990004
DOI https://dx.doi.org/10.2174/15748855113089990004 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Long-Acting Antipsychotic Medications
Current Drug Targets Therapeutic Potential of Morin in Ovalbumin-induced Allergic Asthma Via Modulation of SUMF2/IL-13 and BLT2/NF-kB Signaling Pathway
Current Molecular Pharmacology Dissecting the Therapeutic Potency of Antimicrobial Peptides Against Microbial Biofilms
Current Protein & Peptide Science Editorial
Inflammation & Allergy - Drug Targets (Discontinued) Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science Alzheimers Disease and n-3 Polyunsaturated Fatty Acids: Beneficial Effects and Possible Molecular Pathways Involved
Current Signal Transduction Therapy Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Suppression of HIV Replication In Vitro by CpG and CpG Conjugated to the Non Toxic B Subunit of Cholera Toxin
Current HIV Research The Effects of Caffeine on the Cholinergic System
Mini-Reviews in Medicinal Chemistry New Missions for an Old Agent: Granulocyte-Colony Stimulating Factor in the Treatment of Stroke Patients
Current Medicinal Chemistry Large-Scale Prediction of Drug Targets Based on Local and Global Consistency of Chemical-Chemical Networks
Combinatorial Chemistry & High Throughput Screening Role of Microfluidics in Blood-Brain Barrier Permeability Cell Culture Modeling: Relevance to CNS Disorders
CNS & Neurological Disorders - Drug Targets Chemical Senses in Cancer Patients
Current Pharmaceutical Design Using Extracellular Matrix-Derived Peptides to Alter the Microenvironment for Myocardial Repair
Current Vascular Pharmacology TNF-α Inhibitors from Natural Compounds: An Overview, CADD Approaches, and their Exploration for Anti-inflammatory Agents
Combinatorial Chemistry & High Throughput Screening Innate Immunity, Toll-Like Receptors, and Diabetes
Current Immunology Reviews (Discontinued) The Possibilities and Pitfalls for Anti-Complement Therapies in Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Taking Advantage of Viral Immune Evasion: Virus-Derived Proteins Represent Novel Biopharmaceuticals
Current Medicinal Chemistry Anti-Atherothrombogenic Properties of PEDF
Current Molecular Medicine